



Contacts: Bret L. Udem
Media Relations
Tel. (425) 493-2293
Fax. (425) 493-2010

FOR RELEASE

November 14, 2005

**RENOWNED PATHOLOGIST DR. SCOTT W. BINDER JOINS COMBIMATRIX
MOLECULAR DIAGNOSTICS' SCIENTIFIC ADVISORY BOARD**

Newport Beach, Calif. – (BUSINESS WIRE) –November 14, 2005 – Acacia Research Corporation (Nasdaq: CBMX:ACTG) announced today that Dr. Scott W. Binder, M.D. has joined CombiMatrix's wholly owned subsidiary, CombiMatrix Molecular Diagnostics (CMD), as a member of its Scientific Advisory Board. Dr. Binder is a renowned Dermatopathologist and an internationally known expert in skin diseases with a specialty in pigmented lesions and lymphoid lesions of the skin.

Dr. Binder is a Professor of Clinical Pathology and Dermatology, Chief of Dermatopathology, and Director of Pathology Outreach Services at the David Geffen School of Medicine at UCLA. He is also the founder and Director of one of the few Dermatopathology fellowship training programs in the state of California. Dr. Binder brings a wealth of clinical experience to diagnostic dermatopathology and his comprehensive consultative reports are widely sought.

"We recognize the importance of having leading experts in cancer research on our team as we move toward the commercialization of our cancer diagnostics," stated Matthew Watson, Chief Executive Officer of CMD. "Dr. Binder is well-known and respected and brings a wealth of real-world experience to CMD's Scientific Advisory Board. We look forward to the contribution of his insight and guidance as we begin to launch our diagnostic services."

"I look forward to providing scientific and clinical insight to CMD as they continue developing truly innovative, molecular diagnostic tests for a variety of cancers," said Dr. Binder.

A native of Chicago, Dr. Binder attended the University of Chicago, obtaining a B.A. and an M.D. from the University of Chicago Medical School. He completed his residency at the Department of Pathology and Laboratory Medicine at UCLA and was a Fellow with James Graham, M.D., at the Scripps Clinic and Research Institute in La Jolla, CA. He then completed a Preceptorship with A. Bernard Ackerman, M.D. at New York University. Drs. Graham and Ackerman are internationally-recognized leaders in the field of dermatopathology. Dr. Binder is board certified in Anatomic Pathology, Clinical Pathology, and Dermatopathology http://www.healthcare.ucla.edu/institution/physician?personnel_id=8544.

ABOUT ACACIA RESEARCH CORPORATION

Acacia Research Corporation comprises two operating groups: Acacia Technologies Group and CombiMatrix Group.

The CombiMatrix group is developing a platform technology to rapidly produce customizable arrays, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. The CombiMatrix's group's technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology.

The Acacia Technologies group develops, acquires, and licenses patented technologies. Acacia controls 33 patent portfolios, which include over 130 U.S. patents, and certain foreign counterparts, covering technologies used in a wide variety of industries including audio/video enhancement & synchronization, broadcast data retrieval, computer memory cache coherency, credit card fraud protection, database management, data encryption & product activation, digital media transmission (DMT®), digital video production, dynamic manufacturing modeling, enhanced Internet navigation, high resolution optics, image resolution enhancement, interactive data sharing, interactive television, hearing aid ECS, interstitial Internet advertising, laptop docking station connectivity, microprocessor enhancement, multi-dimensional bar codes, network data storage, resource scheduling, rotational video imaging and spreadsheet automation.

Acacia Research-Acacia Technologies (Nasdaq: ACTG) and Acacia Research-CombiMatrix (Nasdaq: CBMX) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups.

Information about the Acacia Technologies Group and the CombiMatrix Group is available at www.acaciaresearch.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.